Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study
European Journal of Neurology · 2025-07 · 32 (7)
DOI: 10.1111/ene.70179 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 15.07.2025. Verfasst von Roberto Cilia und 59 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. Hauptthemen laut MEDLINE: Carbidopa, Parkinson Disease, Levodopa, Glucosylceramidase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Background
The outcome of levodopa/carbidopa intestinal gel (LCIG) in Parkinson's disease carriers of GBA1 mutations (GBA‐PD) remains uncertain.
Objective
To evaluate the safety and efficacy of LCIG in a large PD cohort, focusing on GBA1 variants.
Methods
This multicenter, retrospective, longitudinal “real‐world” study included consecutive patients with advanced PD treated with LCIG at 31 Italian centers; data were collected at baseline, 1‐, 5‐year, and last‐available follow‐up.
Results
Data from 512 PD patients (59% male, mean age and disease duration at LCIG initiation 67.0 ± 8.0 and 12.9 ± 5.0 years, respectively) were analyzed. GBA1 genotyping was available for 306 patients (60%), of whom 40 (13%) had GBA1 mutations or risk variants. Mean follow‐up on LCIG was 3.9 ± 2.9 years; 5‐year follow‐up data were available for 159 subjects. At baseline, GBA‐PD had a younger age, shorter PD duration, worse cognition, and more hallucinations than noncarriers. At 1‐ and 5‐year follow‐up, LCIG improved motor and non‐motor symptoms, OFF‐time, and dyskinesias in the entire population. In GBA‐PD, MDS‐UPDRS parts I, II, and III scores did not change, while part IV score improved significantly less than in noncarriers; cognition and orthostatic hypotension symptoms worsened more rapidly. Multivariate analysis of predictors for adverse events and LCIG discontinuation found no significant contribution from GBA1 mutation status.
Conclusions
GBA1 status does not increase the risk of adverse events or LCIG discontinuation. LCIG is a safe option for advanced GBA‐PD, even in patients with cognitive impairment at baseline. However, GBA‐PD experiences lower efficacy on motor disability and complications and faster cognitive decline than noncarriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- Azienda Ospedaliera Universitaria S. Anna, U.O. Neurologia, Ferrara, Italy.
- Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.
- Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico san Matteo, Pavia, Italy.
- Parkinson's Centre of Excellence, At King's College Hospital and King's College London, London, UK.
- UO Medicina Interna, Ospedale Nostra Signora Delle Mercede di Lanusei, Lanusei, Italy.
ORCID-Profile: Roberto Cilia, Emanuele Cereda, Miryam Carecchio, Giovanna Calandra-Buonaura, Rosa De Micco, Stefano Tamburin, Marcello M Mascia, Marina Picillo, Giovanni Cossu, Clelia Pellicano, Andrea Pilotto, Micol Avenali, Francesca Di Biasio, Alessandra Nicoletti, Gabriele Imbalzano, Giulia Giannini, Tommaso Schirinzi, Domiziana Rinaldi, Alberto Priori
Förderung
- Ministero della Salute
Zitieren
APA
Cilia, R., Colucci, F., Cereda, E., Elia, A. E., Leta, V., Barca, S., Zibetti, M., Carecchio, M., Bonvegna, S., Calandra-Buonaura, G., Cerroni, R., De Micco, R., Tamburin, S., Magistrelli, L., Lena, F., Mascia, M. M., Picillo, M., Cossu, G., Marano, M., …, & Priori, A. (2025). Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study. European Journal of Neurology, 32(7). https://doi.org/10.1111/ene.70179
Vancouver
Cilia R, Colucci F, Cereda E, Elia AE, Leta V, Barca S, et al. Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study. European Journal of Neurology. 2025;32(7). doi:10.1111/ene.70179
BibTeX
@article{Cilia2025,
author = {Cilia, Roberto and Colucci, Fabiana and Cereda, Emanuele and Elia, Antonio E and Leta, Valentina and Barca, Silvia and Zibetti, Maurizio and Carecchio, Miryam and Bonvegna, Salvatore and Calandra-Buonaura, Giovanna and Cerroni, Rocco and De Micco, Rosa and Tamburin, Stefano and Magistrelli, Luca and Lena, Francesco and Mascia, Marcello M and Picillo, Marina and Cossu, Giovanni and Marano, Massimo and Zampogna, Alessandro and Pellicano, Clelia and Fioravanti, Valentina and Pilotto, Andrea and Zangaglia, Roberta and Avenali, Micol and Sorbera, Chiara and Di Biasio, Francesca and Arienti, Federica and Nicoletti, Alessandra and Bagella, Caterina and Malaguti, Maria Chiara and Ranghetti, Alessandra and Caputo, Elena and Alimonti, Dario and Torre, Elena and Oggioni, Gaia D and Leuzzi, Catia and Romito, Luigi M and Andreasi, Nico Golfrè and Devigili, Grazia and Telese, Roberta and Braccia, Arianna and Gaudiano, Gianfranco and Mazzetti, Samanta and Invernizzi, Federica and Garavaglia, Barbara and Imbalzano, Gabriele and Ledda, Claudia and Antenucci, Pietro and Gozzi, Andrea and Bonato, Giulia and Percetti, Marco and Giannini, Giulia and Sambati, Luisa and Schirinzi, Tommaso and D'Anna, Martina and Rinaldi, Domiziana and Cavallieri, Francesco and Liccari, Marco and Priori, Alberto},
title = {Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {7},
doi = {10.1111/ene.70179}
}
EUVIMED